

Disease/Condition name	No of detectable genes/markers	Genes	Method	Price (EUR)
Breast and Ovarian/ Endometrial Cancer	23	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MEN1, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PTCH1, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53, XRCC2	NGS NGS with CNV	1030 1400
	2	BRCA1, BRCA2	NGS MLPA NGS+MLPA	535 535 803
Cancer Predisposition	102	AIP, ALK, APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN1C, CDKN2A, CEBPA, CEP57, CHEK2, CYLD, DDB2, DICER1, DIS3L2, EGFR, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, EZH2, FANCA, FANCB, FANCC, FANCD2 (excluding exon 15, 16), FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GATA2, GPC3, HNF1A, HOXB13, HRAS, KIT, MAX, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NSD1, NTHL1, PALB2, PHOX2B, POLD1, PRF1, PRKAR1A, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RHBDF2, RUNX1, SBDS, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCB1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1, XPA, XPC, XRCC2	NGS NGS with CNV	1030 1400
	1	RB1	MLPA	310
	1	WT1	MLPA	310
	2	NF1, NF2	MLPA	1030
Familial Adenomatous Polyposis	1	APC	NGS MLPA	450 310
	17	BRCA2, BRIP1, ERCC4, FANCA, FANCB, FANCC, FANCD2 (excluding exons 15, 16), FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, PALB2, RAD51C, SLX4, XRCC2	NGS NGS with CNV	1030 1400
Fanconi Anemia	4	FANCA, FANCB, FANCD2, PALB2	MLPA	1070
	3	MLH1, MSH2, MSH6	NGS NGS with CNV	1030 1400
Lynch Syndrome	1	MLH1	Sanger Sequencing	515
	1	MSH2		515
	1	MSH6		515
	2	MLH1, MSH2	MLPA	310
	1	MSH6	MLPA	310
Melanoma	3	CDK4, CDKN2A, MITF	NGS NGS with CNV	1030 1400
	4	CDK4, CDKN2A, CDKN2B, MITF	MLPA	590
Microsatellite instability	NA/7		Fragment Analysis	175

Disease/Condition name	No of detectable genes/markers	Genes	Method	Price (EUR)
MUTYH-associated Polyposis	1	MUTYH	Sanger Sequencing	257
	1	MUTYH	MLPA	310
	1/2	MUTYH	RFLP	170
Nijmegen Breakage Syndrome	1	NBN	Sanger Sequencing	788
	1/1	NBN		90
Polyposis Syndromes	6	APC, BMPR1A, MUTYH, PTEN, SMAD4, STK11	NGS NGS with CNV	1030 1400
	3	BMPR1A, PTEN, SMAD4	MLPA	590
	1	STK11	MLPA	310
Prostate Cancer	9	BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, NBN, TP53	NGS NGS with CNV	1030 1400
Thyroid Cancer	10	APC, CDC73, DICER1, MEN1, PRKAR1A, PTEN, RET, SDHB, SDHD, TP53	NGS NGS with CNV	1030 1400
	3	SDHB, SDHC, SDHD	MLPA	590
	1	MEN1	MLPA	310
Von Hippel-Lindau Disease	1	VHL	Sanger Sequencing	267
Whole Exome Sequencing (WES)		Solo sample	NGS NGS with CNV	1300 1700
		Trio samples	NGS NGS with CNV	2600 3400
Whole Genome Sequencing (WGS)		Solo sample	NGS	3635
		Trio samples		7449

Version: 2019-06-28

Service includes

- DNA extraction
- Genotyping
- Bioinformatic analysis of detected variants
- Detected variants available in Excel format (on request)
- Validation of phenotype/diagnosis associated known or possibly pathogenic variants
- Clinical and biological interpretation
- Results delivery by registered mail (on request)
- TAT 2-9 weeks, excl. WES 10 weeks and WGS 15 weeks

Online ordering, specimen requirements and shipping instructions are available at www.asperbio.com.